# REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual P&L / Income Statement

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: 2024-01-01 to 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-05, accession number 0001804220-25-000011
- Page: https://plicit.ai/financials/regn/fy2024-annual-income-statement
- Chart image: https://plicit.ai/charts/regn-fy2024-annual-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2024-01-01 through 2024-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue from contract with customer**: 14,202,000,000 US dollars
- **Cost of revenue (calculated)**: 1,970,500,000 US dollars
- **Gross profit (calculated)**: 12,231,500,000 US dollars
- **Operating expenses (calculated)**: 8,240,800,000 US dollars
- **Income from operations**: 3,990,700,000 US dollars
- **Total other income (expense)**: 789,200,000 US dollars
- **Income before income taxes**: 4,779,900,000 US dollars
- **Income tax expense**: 367,300,000 US dollars
- **Net income**: 4,412,600,000 US dollars
- **ELYEA HD And EYLEA - UNITED STATES**: 5,968,200,000 US dollars
- **ELYEA HD - UNITED STATES**: 1,201,100,000 US dollars
- **Evkeeza - UNITED STATES**: 125,700,000 US dollars
- **EYLEA Net Product Sales - UNITED STATES**: 4,767,100,000 US dollars
- **Inmazeb - UNITED STATES**: 76,800,000 US dollars
- **Libtayo - UNITED STATES**: 787,300,000 US dollars
- **Libtayo - Rest Of World**: 429,500,000 US dollars
- **Praluent - UNITED STATES**: 241,700,000 US dollars
- **Undisclosed (calculated)**: 604,600,000 US dollars
- **Cost of goods sold and of collaboration and contract manufacturing**: 1,970,500,000 US dollars
- **Other operating expense (income), net**: 53,400,000 US dollars
- **Acquired in-process research and development**: 101,000,000 US dollars
- **Research and development**: 5,132,000,000 US dollars
- **Selling, general, and administrative**: 2,954,400,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service

- Page: https://plicit.ai/financials/regn/fy2024-annual-income-statement/revenue-by-product-and-service
- Chart image: https://plicit.ai/charts/regn-fy2024-annual-revenue-by-product-and-service-sankey.png

Income statement for 2024-01-01 through 2024-12-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue from contract with customer**: 14,202,000,000 US dollars
- **Cost of revenue (calculated)**: 1,970,500,000 US dollars
- **Gross profit (calculated)**: 12,231,500,000 US dollars
- **Operating expenses (calculated)**: 8,240,800,000 US dollars
- **Income from operations**: 3,990,700,000 US dollars
- **Total other income (expense)**: 789,200,000 US dollars
- **Income before income taxes**: 4,779,900,000 US dollars
- **Income tax expense**: 367,300,000 US dollars
- **Net income**: 4,412,600,000 US dollars
- **Net product sales**: 7,629,200,000 US dollars
- **Collaboration revenue**: 6,057,800,000 US dollars
- **Other revenue**: 515,000,000 US dollars
- **Cost of goods sold and of collaboration and contract manufacturing**: 1,970,500,000 US dollars
- **Other operating expense (income), net**: 53,400,000 US dollars
- **Acquired in-process research and development**: 101,000,000 US dollars
- **Research and development**: 5,132,000,000 US dollars
- **Selling, general, and administrative**: 2,954,400,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.